Satoshi Itano

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 108 citations · Full text

Medicine, Nephrology, Pharmacotherapy +11

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Natalie Staplin, Richard Haynes, PK Judge et al. · The Lancet Diabetes & Endocrinology · 2023 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients.

Yoshihiro Shimauchi, Masatoshi Tanaka, Ryoko Kuromatsu et al. · Oncology Reports · 2000 · 66 citations

Medicine, Oncology, Pathology +16

Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice

Hideki Iwamoto, Shigeo Shimose, Yu Noda et al. · Cancers · 2021 · 59 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Prophylactic Lamivudine Administration Prevents Exacerbation of Liver Damage in HBe Antigen Positive Patients with Hepatocellular Carcinoma Undergoing Transhepatic Arterial Infusion Chemotherapy

Hiroaki Nagamatsu, Satoshi Itano, Sakae Nagaoka et al. · The American Journal of Gastroenterology · 2004 · 55 citations

Medicine, Oncology, Pharmacotherapy +17